** Brokerage RBC Capital Markets initiates coverage on Exact Sciences EXAS.O with "perform" rating
** Brokerage sets PT at $52, representing over 12% upside to the stock's last close
** "By building market awareness for Cologuard while successfully navigating the FDA approval process and payor reimbursement requirements, EXAS has established itself as a leader in the oncology Screening sector of Liquid Biopsy" - RBC Capital Markets
** Brokerage adds that low switching costs and the appeal of a blood-based test may make their (company's) moat difficult to defend
** Says company will need to navigate competitive pricing from new entrants in colorectal cancer screening
** Twenty-three of 27 brokerages rate stock "buy" or higher, and four "hold"; with a median PT of $69.7, according to data compiled by LSEG
** Stock is down over 24% YTD, including session moves; EXAS shed 24% in 2024
(Reporting by Ateev Bhandari in Bengaluru)
((Ateev.Bhandari@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。